semaglutide step 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Semaglutide: The Drug of Today

Mohini Guleria, Jeyachitra Amirdhanayagam, Haladhar D Sarma et al

The renal clearance profile of retatrutide has not been fully characterised in published data

In research, Apolipoprotein E has been predictive of neurodevelopmental dysfunction following cardiac surgery

Following any potential approval, health technology appraisal bodies would evaluate the drug's clinical and cost-effectiveness before recommending its use within NHS services: this includes NICE for England, the Scottish Medicines Consortium (SMC) for Scotland, and the All Wales Medicines Strategy Group (AWMSG) for Wales

Tirzepatide slows gastric emptying, which could theoretically affect absorption of oral medications like levothyroxine